Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 18/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 18/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919619 | 0.80 | ITGA4 (0.49) | ITGA4ITGB7ITGB1 | |
| SCHEMBL509614 | 0.78 | CRHR1 (0.41) | ITGA4ITGB7RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL15604110 | 0.77 | RAB9A (0.42) | RAB9ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL28615978 | 0.76 | ALDH1A1 (0.38) | ITGA4ITGB7RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4512412 | 0.75 | ITGA4 (0.70) | ITGA4ITGB7ITGB1 | |
| SCHEMBL4512416 | 0.75 | ITGA4 (0.70) | ITGA4ITGB7ITGB1 | |
| SCHEMBL22016864 | 0.74 | ALDH1A1 (0.41) | ITGA4ITGB7RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL919618 | 0.73 | L3MBTL1 (0.40) | ITGA4ITGB7RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL21835475 | 0.71 | MAPT (0.45) | ITGA4ITGB7RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29384915 | 0.71 | MAPT (0.45) | ITGA4ITGB7RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005077915-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | disclosed |